Vincent Castonguay

Lavallée LT, Fitzpatrick R, Wood LA, Basiuk J, Knee C, Cnossen S, Mallick R, Witiuk K, Vanhuyse M, Tanguay S, Finelli A, Jewett MAS, Basappa N, Lattouf JB, Gotto GT, Al-Asaaed S, Bjarnason GA, Moore R, North S, Canil C, Pouliot F, Soulières D, Castonguay V, Kassouf W, Cagiannos I, Morash C, Breau RH

Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC)

J Cancer Educ, 34 (1), 2019.

Résumé | Liens:

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC,

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

N Engl J Med, 378 (22), 2018.

Résumé | Liens:

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM,

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer

N Engl J Med, 379 (21), 2018.

Résumé | Liens:

Castonguay V, Wilson MK, Diaz-Padilla I, Wang L, Oza AM

Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer

Cancer, 121 (3), 2015.

Résumé | Liens:

Castonguay V, Lheureux S, Welch S, Mackay HJ, Hirte H, Fleming G, Morgan R, Wang L, Blattler C, Ivy PS, Oza AM

A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia

Gynecol Oncol, 134 (2), 2014.

Résumé | Liens:

Poulin LD, Riopel J, Castonguay V, Mac-Way F

Acute oxalate nephropathy induced by oral high-dose vitamin C alternative treatment

Clin Kidney J, 7 (2), 2014.

| Liens:

Matulonis UA, Lee J, Lasonde B, Tew WP, Yehwalashet A, Matei D, Behbakht K, Grothusen J, Fleming G, Lee NK, Arnott J, Bray MR, Fletcher G, Brokx RD, Castonguay V, Mackay H, Sidor CF, Oza AM

ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer

Eur J Cancer, 49 (1), 2013.

Résumé | Liens:

Sahebjam S, Bedard PL, Castonguay V, Chen Z, Reedijk M, Liu G, Cohen B, Zhang WJ, Clarke B, Zhang T, Kamel-Reid S, Chen H, Ivy SP, Razak AR, Oza AM, Chen EX, Hirte HW, McGarrity A, Wang L, Siu LL, Hotte SJ

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)

Br J Cancer, 109 (4), 2013.

Résumé | Liens:

Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study

Clin Cancer Res, 19 (19), 2013.

Résumé | Liens:

Oza AM, Castonguay V, Tsoref D, Diaz-Padilla I, Karakasis K, Mackay H, Welch S, Weberpals J, Hoskins P, Plante M, Provencher D, Tonkin K, Covens A, Ghatage P, Gregoire J, Hirte H, Miller D, Rosen B, Maroun J, Buyse M, Coens C, Brady MF, Stuart GC

Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective

Curr Oncol, 18 Suppl 2 , 2011.

Résumé | Liens: